Adding targeted therapy to TACE improves PFS for unresectable nonmetastatic liver cancer

Progression-free survival findings from two phase 3 clinical trials support the use of targeted therapies in combination with transarterial chemoembolisation for the treatment of patients with unresectable, nonmetastatic hepatocellular carcinoma.